El Foro de El Anzuelo Club de Pesca
[
Inicio
] [
Nuevo Tema
]
Autor
Titulo
Mensaje
[citar]Pleased to meet you http://hqporner.in.net/ porneq The approval was based on the Phase III GRID study that demonstrated a statistically significant improvement in progression-free survival (PFS) for Stivarga compared to placebo (4.8 months versus 0.9 months) in patients with GIST whose disease had progressed after treatment with Glivec and Sutent. [/citar]